Key takeaway: NIPT is a highly accurate screening test (99%+ sensitivity for common trisomies) that can be performed from 9-10 weeks with zero miscarriage risk. Amniocentesis and CVS are diagnostic procedures that provide definitive answers but carry a small miscarriage risk (~1/500 for amniocentesis). NIPT results are reported as high-risk or low-risk, not positive or negative.
The Two Categories of Prenatal Genetic Testing
Prenatal genetic testing separates into two distinct categories, and understanding the difference is critical for informed decision-making:
- Screening tests estimate the likelihood that a fetus has a chromosomal condition. They do not give a yes/no answer — they tell you whether your pregnancy is at higher or lower risk. NIPT is a screening test. A high-risk NIPT result means further diagnostic testing is recommended, not that the fetus definitely has the condition.
- Diagnostic tests provide a definitive answer about whether a fetus has a specific chromosomal condition. Amniocentesis and chorionic villus sampling (CVS) are diagnostic tests. They analyze fetal cells directly rather than cell-free DNA fragments circulating in maternal blood.
According to ACOG Practice Bulletin 226 (2020), NIPT should be offered to all pregnant patients regardless of age or baseline risk, but patients must understand that NIPT is a screening test and that diagnostic testing is necessary to confirm any high-risk result.
NIPT vs Amniocentesis vs CVS: Head-to-Head Comparison
| Feature | NIPT | Amniocentesis | CVS |
|---|---|---|---|
| Test type | Screening | Diagnostic | Diagnostic |
| Timing | 9-10 weeks onward | 15-20 weeks | 10-13 weeks |
| Procedure | Blood draw from arm | Needle through abdomen into amniotic sac | Catheter through cervix or needle through abdomen into placenta |
| Miscarriage risk | None | ~1 in 500 (0.2%) | ~1 in 455 (0.22%) |
| Trisomy 21 sensitivity | 99.4-99.9% | >99.9% | >99% |
| Conditions detected | Trisomies 21, 18, 13; sex aneuploidies; select microdeletions | Full karyotype + microarray (detects thousands of disorders) | Full karyotype + microarray |
| Turnaround time | 5-10 days | Karyotype: 10-14 days; FISH: 2-3 days | Karyotype: 10-14 days; FISH: 2-3 days |
| Cost (self-pay) | $349-$1,500 | $1,500-$3,000+ | $1,500-$3,000+ |
Miscarriage risk context: The widely cited 1 in 500 miscarriage risk for amniocentesis comes from a 2016 ACOG practice bulletin that reviewed modern procedure data from experienced centers using ultrasound guidance. Earlier studies from the 1970s-1990s reported higher rates (~1 in 200), but modern techniques — particularly continuous ultrasound guidance — have substantially reduced the risk. A 2019 systematic review in Ultrasound in Obstetrics & Gynecology found a procedure-related loss rate of approximately 0.1% (1 in 1,000) in experienced centers.
How NIPT Works: Cell-Free DNA Analysis
During pregnancy, small fragments of DNA from the placenta (which is genetically identical to the fetus in nearly all cases) cross into the maternal bloodstream. By roughly 10 weeks of pregnancy, this cell-free fetal DNA (cffDNA) constitutes approximately 4-15% of the total cell-free DNA in the mother's blood — known as the fetal fraction. NIPT isolates and counts these fragments to determine whether specific chromosomes are overrepresented, indicating a trisomy (three copies instead of two).
There are two main NIPT methodologies:
- SNP-based NIPT (used by Natera Panorama): Looks at thousands of single nucleotide polymorphisms (SNPs) across the genome and compares fetal and maternal patterns to detect chromosomal abnormalities. This approach requires a maternal blood sample and can distinguish maternal from fetal DNA, which reduces false positives from maternal chromosomal abnormalities.
- Whole-genome counting (used by Labcorp MaterniT 21 PLUS and most other NIPTs): Sequences all cell-free DNA fragments in the sample and counts the number of fragments mapping to each chromosome. An overrepresentation of chromosome 21 fragments suggests trisomy 21.
Natera Panorama has performed over 2 million tests since launch, and Labcorp MaterniT 21 PLUS has been validated in studies involving over 1.9 million pregnancies. For common trisomies, both approaches achieve sensitivity and specificity exceeding 99%.
Why Positive Predictive Value Matters More Than Sensitivity
One of the most misunderstood aspects of NIPT is the difference between sensitivity and positive predictive value (PPV). Sensitivity tells you: of pregnancies that are truly affected, what percentage will NIPT catch? PPV tells you: of pregnancies where NIPT returns a high-risk result, what percentage are truly affected?
PPV depends heavily on the mother's age — because the baseline prevalence of chromosomal abnormalities increases with maternal age:
| Maternal Age | Trisomy 21 PPV | Trisomy 18 PPV |
|---|---|---|
| 25 years | ~50-70% | ~30-50% |
| 35 years | ~85-90% | ~65-80% |
| 40 years | >92% | >85% |
Source: 2022 meta-analysis of 1.9 million NIPT results, Ultrasound in Obstetrics & Gynecology. This means that for a 25-year-old woman, roughly 30-50% of high-risk NIPT results are actually false positives — a diagnostic test (amniocentesis or CVS) is essential before making any irreversible decisions.
What to Expect: The Testing Process
NIPT
- A standard blood draw from your arm — identical to any routine blood test
- Sample is sent to the lab (Natera, Labcorp, Quest, etc.)
- Results return in 5-10 days, depending on the lab
- Results are reported as "low risk" or "high risk" for each condition, often with a specific risk score (e.g., >1/10,000 for low risk)
- If high risk: your provider refers you to a genetic counselor or maternal-fetal medicine specialist to discuss diagnostic testing
Amniocentesis
- Performed between 15-20 weeks of pregnancy
- Ultrasound is used continuously to guide a thin needle through your abdomen into the amniotic sac
- About 20 mL of amniotic fluid is withdrawn (roughly 2 tablespoons — your body replaces it within hours)
- Fluid contains fetal cells that are cultured and analyzed; results return in 10-14 days for karyotype, 2-3 days for FISH (rapid results for chromosomes 13, 18, 21, X, Y)
- Mild cramping is common post-procedure; most patients return to normal activities within 24 hours
CVS (Chorionic Villus Sampling)
- Performed between 10-13 weeks — the main advantage over amniocentesis is earlier timing
- A small sample of chorionic villi (placental tissue) is collected, either through the cervix (transcervical) or through the abdomen (transabdominal), depending on placental location
- Placental tissue is genetically identical to the fetus in >98% of cases; in rare cases (<2%), confined placental mosaicism can produce discrepant results
- Results return in similar timeframes to amniocentesis
Making the Decision: Screening vs Diagnostic Testing
The decision between NIPT alone and proceeding to diagnostic testing is deeply personal and should be made in consultation with a genetic counselor or maternal-fetal medicine specialist. Factors to consider:
- Your tolerance for uncertainty — Are you comfortable with a screening result that says low risk (not zero risk), or do you need definitive answers?
- What you would do with the information — If you would not terminate a pregnancy under any circumstances, you may still want diagnostic testing to prepare medically for a child with special needs
- Your baseline risk — Advanced maternal age, abnormal ultrasound findings, prior pregnancy with a chromosomal abnormality, or positive carrier screening all increase the utility of diagnostic testing
- Risk tolerance for the procedure itself — The ~1 in 500 to 1 in 1,000 miscarriage risk for amniocentesis must be weighed against the probability that NIPT missed something (false negative) or incorrectly flagged something (false positive)
Compare testing options for every stage of your health journey
Browse our independent directory of DNA tests — from carrier screening to whole genome sequencing.
Compare Tests Browse DirectoryFrequently Asked Questions
Does NIPT show the baby's sex?
Yes. Because NIPT analyzes cell-free DNA that includes fetal sex chromosomes, it can determine fetal sex with 99%+ accuracy as early as 9-10 weeks. Most NIPT providers will report fetal sex if the patient opts in. NIPT also screens for sex chromosome aneuploidies (Turner syndrome, Klinefelter syndrome, Triple X, and Jacobs syndrome), though the positive predictive value for these conditions is lower than for common trisomies.
What if the fetal fraction is too low for NIPT?
A low fetal fraction (typically below 4%) results in a "no-call" or inconclusive result, which occurs in approximately 1-5% of NIPT tests. Common causes include testing too early (before 10 weeks), high maternal BMI (higher blood volume dilutes fetal DNA), and certain medications. A maternal-fetal medicine specialist will typically recommend either a repeat blood draw in 1-2 weeks or proceeding directly to diagnostic testing. Importantly, low fetal fraction is independently associated with a slightly increased risk of certain chromosomal abnormalities — it should not be ignored.
Can NIPT be done for twin pregnancies?
Yes, NIPT is validated for twin pregnancies, though the test performance is slightly reduced compared to singletons. For dichorionic twins (separate placentas), NIPT for trisomy 21 has a sensitivity of approximately 96-99%, and Panorama is the only NIPT that can distinguish zygosity (identical vs fraternal twins) via its SNP-based approach. For monochorionic twins (shared placenta), the fetal DNA is presumed to be identical and NIPT performance is similar to singletons. Diagnostic confirmation of any high-risk NIPT result in twins requires amniocentesis, which is more technically complex in twin pregnancies.